Surfactant replacement therapy for severe neonatal respiratory distress syndrome: implications for nursing care
References (13)
- et al.
Artificial surfactant therapy in hyaline membrane disease
Lancet
(1980) - et al.
Exogenous human surfactant for treatment of severe respiratory distress syndrome: a randomised prospective clinical trial
Journal of Pediatrics
(1985) - et al.
Trial of artificial lung surfactant and its effect on very premature babies
Lancet
(1981) - et al.
Risk of respiratory distress syndrome related to gestational age, route of delivery and maternal diabetes
American Journal of Obstetrics and Gynecology
(1971) Categories of babies requiring neonatal care
Archives of Disease in Childhood
(1985)- et al.
British births 1970, Vol 1, the first week of life
(1975)
There are more references available in the full text version of this article.
Cited by (5)
Simulation training for surfactant replacement therapy: Implications for clinical practice
2014, Journal of Neonatal NursingCitation Excerpt :Premature infants are often surfactant-deficient and have an increased risk of respiratory distress syndrome (RDS); a condition associated with an increase in morbidity and mortality (Walsh et al., 2013). Sittlington, Tubman, and Halliday noted that RDS contributes to nearly “32% of all deaths in the first week of life” (1991, p. 20). Therefore, premature infants are given surfactant replacement therapy (SRT) for immature lung development or to prevent RDS, within 30 min of birth, or as a rescue treatment 2–12 h after birth.
Randomised controlled trial of an aggressive nutritional regimen in sick very low birthweight infants
1997, Archives of Disease in Childhood: Fetal and Neonatal EditionThe cost of neonatal care: Reviewing the evidence
1995, Sozial- und Präventivmedizin SPMEnergy requirements in sick preterm babies
1994, Acta PædiatricaThe influence of nutrition on neonatal respiratory muscle function
1992, Intensive Care Medicine
Copyright © 1991 Published by Elsevier Ltd.